Statins for the “SMuRFLess But Inflamed”
Why the study?
Does rosuvastatin 20 mg reduce major adverse cardiovascular events compared to placebo in primary prevention individuals with elevated hsCRP (>2 mg/L) and no standard modifiable cardiovascular risk factors?
Key Points
- To assess whether statin therapy reduces major adverse cardiovascular outcomes in primary prevention among individuals with silent systemic inflammation who lack standard modifiable cardiovascular risk factors.
- Subgroup analysis of 8,278 participants from the randomized JUPITER trial who had no standard modifiable cardiovascular risk factors but had elevated hsCRP levels >=2 mg/L.
- Participants received rosuvastatin 20 mg daily or placebo, with outcome models adjusted for body mass index and estimated glomerular filtration rate.
- Incidence rates were lower with rosuvastatin for myocardial infarction (0.10 vs 0.32; HR: 0.31; 95% CI: 0.15-0.66) and arterial revascularization (0.39 vs 0.62; HR: 0.61; 95% CI: 0.40-0.93).
- Stroke incidence was 0.12 with rosuvastatin versus 0.23 with placebo, showing a non-statistically significant reduction (HR: 0.53; 95% CI: 0.25-1.09).
Structured PICO
Does rosuvastatin 20 mg reduce major adverse cardiovascular events compared to placebo in primary prevention individuals with elevated hsCRP (>2 mg/L) and no standard modifiable cardiovascular risk factors?
P
Population
8,278 primary prevention participants from the JUPITER trial with no standard modifiable cardiovascular risk factors other than elevated hsCRP (>2 mg/L), followed for a median of 2 years.
I
Intervention
Rosuvastatin 20 mg
C
Comparator
Placebo
O
Outcome
Major adverse cardiovascular events (adjusted for body mass index and estimated glomerular filtration rate) over a median follow-up of 2 years (maximum 5 years)composite
Main Result
Hazard Ratio: 0.62 (95% CI 0.45–0.85)
Absolute Event Rate: 0.68% vs 1.08%
p-value: p=0.003
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“What is less often discussed is how slow translation to practice can be even when human evidence marks the starting point for discovery. The effectiveness of statin therapy among the “SMuRFLEss but Inflamed” (individuals without SMuRFs [standard modifiable cardiovascular risk factors] yet who are at high vascular risk due to silent inflammation) provides a case study of the complexity involved in translational science derived from human data.”
Implication
Statin therapy with rosuvastatin significantly reduces major adverse cardiovascular events in primary prevention individuals whose only cardiovascular risk factor is elevated hsCRP (>2 mg/L), supporting universal inflammation screening alongside cholesterol screening.
Abstract
No abstract yet. The journal hasn't published one we can show.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Paul M. Ridker (2025) conducted an editorial in Elevated cardiovascular risk due to silent inflammation (hsCRP >2 mg/L) without standard modifiable cardiovascular risk factors (SMuRFLess) (n=8,278). Rosuvastatin vs. Placebo was evaluated on Major adverse cardiovascular events (adjusted for body mass index and estimated glomerular filtration rate) (HR 0.62, 95% CI 0.45-0.85, p=0.003).